NCT04753164已完成2 期
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 136
- 试验地点
- 30
- 主要终点
- Change From Baseline to Week 12 in the Number of Binge Eating (BE) Days Per Week
研究概览
简要总结
Placebo-controlled study to evaluate the efficacy and safety of oral ACT-539313 in the treatment of adults with moderate to severe binge eating disorder
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Criteria assessed at Visit 1:
- •Signed and dated informed consent form prior to any study-mandated procedure.
- •Male or female study participants aged 18 to 55 years at the time of signing the informed consent form.
- •Binge-eating disorder (BED) in accordance with Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) criteria diagnosed using the Structured Clinical Interview for DSM-5 (SCID-5).
- •Self-reported BED severity of at least moderate level, defined as at least 4 BE episodes per week, on average, for a duration of at least 6 months.
- •BED in accordance with Eating Disorder Examination Questionnaire (EDE-Q).
- •Clinical Global Impression of Severity scale (CGI-S) score of ≥
- •For women of childbearing potential (WOCBP): Negative serum pregnancy test at Visit 1; agreement to undertake monthly urine or serum pregnancy tests during the study and up to the EOS visit; agreement to use an acceptable contraceptive method.
- •Criteria assessed at Visit 2:
- •Reporting ≥3 BE days for each of the 2 weeks prior to randomization as documented in the participant's BE diary and with BE diary entries completed for at least 6 days per week during this 2-week period (between Visit 1 and 2).
- •CGI-S score of ≥
- •For WOCBP: negative urine pregnancy test.
排除标准
- •Criteria assessed at Visit 1:
- •BMI < 18.0 kg/m² or > 45 kg/m².
- •Any acute or chronic-persistent psychiatric disorder other than BED diagnosed in the past, including anorexia nervosa, bulimia, psychotic disorders, bipolar disorder, hypomania, or dementia, as defined by the DSM-5 criteria or by the Mini International Neuropsychiatric Interview (MINI©).
- •Use of any medications for the treatment of BED (including lisdexamfetamine [Vyvanse®]), any other eating disorder, obesity, or weight gain, or any other medication that could result in weight gain or weight loss, including over-the-counter and herbal products, within 3 months prior to Screening.
- •Any clinically unstable medical condition, significant medical disorder or acute illness that, in the investigator's opinion, could interfere with the participants ability to comply with study assessments or abide by study restrictions.
- •Criteria assessed at Visit 1 and Visit 2
- •HAMD-17 score ≥ 17 points at Visit 1 and/or Visit
- •Any of the following conditions related to suicidality:
- •Participant is considered to have a suicide risk in the investigator's opinion or has a previous history of suicide attempt within the past 12 months.
- •Participant answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS© assessment at Screening (in the past month). Participants who answer "yes" to this question must be referred to the investigator for follow-up evaluation.
- •Female participants: pregnant, lactating or planning to become pregnant during the projected course of the study.
研究组 & 干预措施
100 mg twice daily (b.i.d.) ACT-539313
Experimental
干预措施: ACT-539313 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Change From Baseline to Week 12 in the Number of Binge Eating (BE) Days Per Week
时间窗: From baseline to Week 12; duration approx. 3.5 months
BE days per week is defined as the number of diary days with at least one confirmed BE episode during the applicable 14-day time interval divided by the total number of diary days, times 7.
次要结局
未报告次要终点
研究者
研究点 (30)
Loading locations...
相似试验
已完成
2 期
Study of ACT-129968 in Adult Patients With Seasonal Allergic RhinitisSeasonal Allergic RhinitisNCT01241214Idorsia Pharmaceuticals Ltd.579
已完成
3 期
Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee ReplacementTotal Knee Arthroplasty (Replacement)NCT00681356Anesiva, Inc.214
已完成
3 期
Phase 3 double blind study of ACT-541468JPRN-jRCT2031200452Kawashima Takayuki490
已完成
3 期
Safety and Efficacy Study to Treat Bacterial VaginosisBacterial VaginosisNCT01621399Medicis Global Service Corporation651
终止
1 期
A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478HealthyNCT04452006Idorsia Pharmaceuticals Ltd.56